Sustained elevation of intraocular pressure after intravitreal anti-vegf agents: What is the evidence?

Retina

Volumn 35, Issue 5, 2015, Pages 841-858

  Dedania, Vaidehi S ^a   Bakri, Sophie J ^b  

^a ALBANY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

age related macular degeneration; bevacizumab; eye; intraocular pressure; intravitreal injection adverse events; ranibizumab; retina; sustained elevation; vascular endothelial growth factor

Indexed keywords

GLUCOCORTICOID; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; EYE INFLAMMATION; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MEDICAL HISTORY; PRESSURE MEASUREMENT; REVIEW; RISK FACTOR; TRABECULAR MESHWORK; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; OCULAR HYPERTENSION; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; OCULAR HYPERTENSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84928990095     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000520     Document Type: Review

References (54)

1. Funk M, Karl D, Georgopoulos M, et al. Neovascular agerelated macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116:2393-2399.
2. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1928-1934.
3. Adamis AP, Aiello LP, D'Amato RA. Angiogenesis and ophthalmic disease. Angiogenesis 1999;3:9-14.
4. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25: 111-118.
5. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: sixmonth primary end point results of a phase III study. Ophthalmology 2010;117:1124-1133.
6. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-1077.
7. Cunningham ET Jr., Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757.
8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration (MARINA). N Engl J Med 2006;355:1419-1431.
9. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-2548.
10. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
11. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006;113:e1-e4.
12. Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 2009;116:S15-S23.
13. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26: 495-511.
14. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-1349.
15. Pong JC. Anterior chamber paracentesis in patients with acute elevation of intraocular pressure. Graefes Arch Clin Exp Ophthalmol 2008;246:463-464.
16. Arnavielle S, Creuzot-Garcher C, Bron AM. Anterior chamber paracentesis in patients with acute elevation of intraocular pressure. Graefes Arch Clin Exp Ophthalmol 2007;245:345-350.
17. Chang W, Chung M. Efficacy of anterior chamber paracentesis in intravitreal triamcinolone injections. Eur J Ophthalmol 2007;17:776-779.
18. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
19. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001.
20. Gragoudas ES, Adamis AP, Cunningham ET Jr., et al. VEGF inhibition study in ocular neovascularization clinical trial group: pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
21. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955-958.
22. Good T, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-1114.
23. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105-110.
24. Segal O, Ferencz JR, Cohen P, et al. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab. IMAJ 2013;15:420-423.
25. Pershing S, Bakri SJ, Moshfeghi DM. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina 2013;44:460-464.
26. Choi DY, Ortube MC, McCannel CA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab and pegaptanib. Retina 2011;31:1028-1035.
27. Bakri SJ, Moshfeghi DM, Francom S, et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal agerelated macular degeneration clinical trials. Ophthalmology 2014;121:1102-1108.
28. Mathalone N, Arodi-Golan A, Sar A, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012;250:1435-1440.
29. Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40: 293-295.
30. Wehrli SJ, Tawse K, Levin MH, et al. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina 2012; 32:1295-1301.
31. Kim D, Nam WH, Kim HK, Yi K. Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure? J Glaucoma 2014;23: 446-448.
32. Hoang QV, Mendonca LS, Della Torre KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012;119:321-326.
33. Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal antivascular endothelial growth factor therapy. Retina 2013;33: 179-187.
34. Menke MN, Salam A, Framme C, Wolf S. Long-term intraocular pressure changes in patient with neovascular age-related macular degeneration with ranibizumab. Ophthalmologica 2013;229:168-172.
35. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012;21:241-247.
36. Drance SM. The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol 1960;64: 494-501.
37. Shukla D, Vidhya N, Prasad NM, et al. Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone. Am J Ophthalmol 2007;144:453-454.
38. Kubota T, Okabe H, Hisatomi T, et al. Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 2006;15:117-119.
39. Shinzato M, Yamashiro Y, Miyara N, et al. Proteomic analysis of the trabecular meshwork of rats in a steroid-induced ocular hypertension model: downregulartion of type I collagen C-propeptides. Ophthalmic Res 2007;39:330-337.
40. Leung YF, Tam PO, Lee WS, et al. The dual role of dexamethasone on anti-inflammation and outflow resistance demonstrated in cultured human trabecular meshwork cells. Mol Vis 2003;9:425-439.
41. Rozsa FW, Reed DM, Scott KM, et al. Gene expression profile of human trabecular meshwork cells in response to long-term dexamethasone exposure. Mol Vis 2006;12:125-141.
42. Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-811.
43. Krohne TU, Eter N, Holz FG, Meyer CH. Interocular pharmacokinetics of bevacizumab after single use intravitreal injections in humans. Am J Ophthalmol 2008;146:508-512.
44. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010;30:887-892.
45. Lui L, Ammar DA, Ross L, et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011;52:1023-1034.
46. Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug interactions. Retina 2008;28:996-1001.
47. Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on culture human trabecular meshwork cells. J Glaucoma 2010;19:437-441.
48. Kernt M, Weige-Lüssen U, Yu M, et al. Bevacizumab is not toxic to human anterior-And posterior-segment cultured cells [German]. Ophthalmologe 2007;104:965-971.
49. Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457-462.
50. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye 2007;21:1541.
51. Theoulakis PE, Lepidas J, Petropoulos IK, et al. Effect of Brimonidine/Timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd 2010;227:280-284.
52. Benz MS, Albini TA, Holz ER, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006;113:1174-1178.
53. Sharei V, Höhn F, Köhler T, et al. Course of intraocular pressure after intravitreal injection of 0.05 ml ranibizumab (Lucentis). Eur J Ophthalmol 2010;20:174-179.
54. Höhn F, Mirshahi A. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application. Graefes Arch Clin Exp Ophthalmol 2010;248: 1371-1375.